King Faisal Specialist Hospital, Riyadh – United Arab Emirates
About Dr. Awatif AlAnazi
Dr. Awatif AlAnazi is a Consultant Paediatric Haematologist/Oncologist specialising in paediatric solid tumours, paediatric sickle cell disease HSCT, paediatric neuroblastoma, and rhabdomyosarcoma — an experienced paediatric oncologist in Riyadh, Saudi Arabia providing comprehensive care for international families. She has contributed to extensive research covering paediatric bone marrow transplant, neuroblastoma epidemiology, and paediatric solid tumour outcomes.
- Consultant Paediatric Haematologist/Oncologist specialising in solid tumours and paediatric HSCT
- Active author and co-author across paediatric haematology and oncology research
- Published researcher on paediatric sickle cell HSCT outcomes
- Contributor to Saudi paediatric neuroblastoma and rhabdomyosarcoma outcomes research
- Co-author on a 23-year BMT experience in children under 2 years of age
Qualifications & Credentials
Medical Degrees
- MBBS — Bachelor of Medicine and Bachelor of Surgery
- Paediatric Residency
Fellowships & Special Training
- Fellowship in Paediatric Haematology/Oncology
- Subspecialty Training in Paediatric Solid Tumours and Paediatric BMT
Certifications & Accreditations
- Saudi Commission for Health Specialties (SCFHS) — Registered Consultant
- International Society of Paediatric Oncology (SIOP) — Member
- American Society of Haematology (ASH) — Member
Areas of Expertise
Major Conditions Treated
- Paediatric Neuroblastoma (Including High-Risk)
- Rhabdomyosarcoma
- Wilms Tumour
- Paediatric Sickle Cell Disease (HSCT Candidates)
- Paediatric Acute Leukaemia
- Germ Cell Tumours
- Ewing Sarcoma
- Osteosarcoma
- Paediatric Brain Tumours
- Hepatoblastoma
Sub-specialties
- Paediatric Solid Tumour Oncology: Risk-stratified multidisciplinary treatment for paediatric neuroblastoma, rhabdomyosarcoma, Wilms tumour, and other solid tumours — a trusted paediatric oncologist in Riyadh for international families.
- Paediatric Sickle Cell HSCT: Evaluation and peri-transplant care for paediatric sickle cell disease patients undergoing haematopoietic stem cell transplantation.
- Paediatric BMT in Very Young Children: Contributing author on 23-year institutional experience of bone marrow transplantation in children under 2 years of age.
Advanced Procedures & Treatments
- Risk-Stratified Chemotherapy (COJEC, VAC, VDC/IE)
- Autologous and Allogeneic HSCT Coordination
- Anti-GD2 Immunotherapy (Dinutuximab)
- Targeted Therapy for Paediatric Solid Tumours
- Bone Marrow Harvest and Stem Cell Collection
- Multidisciplinary Tumour Board Management
- Paediatric Supportive and Palliative Care
- Long-Term Survivorship Follow-Up
Professional Experience
Current Affiliation
- Consultant, Paediatric Haematology/Oncology (Solid Tumours) — King Faisal Specialist Hospital & Research Centre (KFSHRC), Riyadh, Saudi Arabia (Present)
Past Affiliations
- Paediatric Haematology/Oncology Fellowship — completed prior to consultancy at KFSHRC
Academic & Research Roles
- Contributing author to extensive peer-reviewed paediatric haematology/oncology research
- Participant — KFSHRC Paediatric Multidisciplinary Tumour Board
- Investigator — paediatric HSCT and solid tumour outcome studies
Key Achievements
- extensive peer-reviewed publication record in paediatric oncology
- Co-author on a recent paediatric sickle cell HSCT outcomes study
- Contributor to Saudi paediatric neuroblastoma epidemiology research
- Co-author on Blood 2019;134:1969 bone marrow harvest volume study and Saudi paediatric rhabdomyosarcoma outcomes
Awards & Recognitions
National & International Awards
- Information not publicly available.
Professional Memberships
- International Society of Paediatric Oncology (SIOP)
- American Society of Haematology (ASH)
- Saudi Paediatric Association
- Saudi Society of Haematology
Research & Publications
Published Papers (Selected)
- Al-Jefri A, AlAnazi A, et al. Haematopoietic Stem Cell Transplantation for Paediatric Sickle Cell Disease. Mediterranean Journal of Hematology and Infectious Diseases. 2025;e2025030.
- AlAnazi A, et al. Paediatric Neuroblastoma — Saudi Epidemiology and Outcomes.
- AlAnazi A, et al. Bone Marrow Harvest Volume in Paediatric Donors. Blood. 2019;134(Suppl):1969.
- AlAnazi A, et al. Paediatric Rhabdomyosarcoma — Saudi Clinical Outcomes. 2023. PMC9875671.
- AlAnazi A, et al. 23-Year Experience of Paediatric Bone Marrow Transplantation in Children <2 Years.
Ongoing Research & Clinical Interests
- Paediatric HSCT outcomes in sickle cell disease
- High-risk paediatric neuroblastoma management
- Paediatric rhabdomyosarcoma risk stratification
- Paediatric BMT in very young children
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (INR) | Estimated Cost (USD) |
|---|---|---|
| Paediatric Oncology Consultation | ₹1,000 – ₹2,500 | $12 – $30 |
| Paediatric Chemotherapy (per cycle) | ₹25,000 – ₹1,75,000 | $300 – $2,100 |
| Paediatric Stem Cell Transplant | ₹18,00,000 – ₹35,00,000 | $21,700 – $42,200 |
| Tumour Biopsy & Molecular Profiling | ₹15,000 – ₹75,000 | $180 – $900 |
| Targeted / Immunotherapy (per cycle) | ₹80,000 – ₹3,00,000 | $960 – $3,600 |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Dr. Awatif AlAnazi use in Paediatric Haematology / Oncology — Solid Tumours treatment?
Dr. Awatif AlAnazi uses advanced paediatric oncology and transplant technologies including risk-stratified chemotherapy regimens (COJEC, VAC, VDC/IE), autologous and allogeneic stem cell transplantation coordination, anti-GD2 immunotherapy for neuroblastoma (dinutuximab), targeted therapy for paediatric sarcomas, bone marrow harvest and stem cell collection, and multidisciplinary tumour board coordination. Virtual consultations and remote second opinions are also available to international families through Cancer Rounds.
2. What conditions does Dr. Awatif AlAnazi specialize in treating?
Dr. Awatif AlAnazi specialises in Paediatric Solid Tumour Oncology and Paediatric HSCT, treating paediatric neuroblastoma (including high-risk), rhabdomyosarcoma, Wilms tumour, paediatric sickle cell disease (HSCT candidates), paediatric acute leukaemia, germ cell tumours, Ewing sarcoma, osteosarcoma, paediatric brain tumours, and hepatoblastoma. International families seeking the best paediatric oncologist in India or Saudi Arabia benefit from her extensive published experience.
3. How do I book an appointment with Dr. Awatif AlAnazi?
Appointments with Dr. Awatif AlAnazi can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. Awatif AlAnazi?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Dr. Awatif AlAnazi, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Dr. Awatif AlAnazi offer second opinions for Paediatric Haematology / Oncology — Solid Tumours cases?
Yes. Second opinion consultations for Paediatric Solid Tumour and paediatric HSCT cases can be arranged via Cancer Rounds, enabling international families to review complex paediatric oncology cases with Dr. Awatif AlAnazi.
